3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
7
Fallopian Tube Neoplasms
4
Melanoma
3
Breast Neoplasms
3
Stomach Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Adenocarcinoma
1
Interventions
pembrolizumab
24
Nivolumab
15
Magnetic Resonance Spectroscopy
7
Ipilimumab
6
avelumab
5
atezolizumab
5
Specimen Handling
5
Docetaxel
4
lenvatinib
3
durvalumab
3
Paclitaxel
3
Cyclophosphamide
3
Carboplatin
3
fludarabine
2
cabozantinib
2
aldesleukin
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
FAPI-46
2
zanidatamab
1
veliparib
1
tislelizumab
1
spartalizumab
1
soluble LAG-3 protein, human
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Gynecologic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled